Abstract
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it i......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
